创新药龙头率先盈利，资金布局医药板块，生物医药ETF（512290）连续4日迎净流入

Core Viewpoint - The leading innovative pharmaceutical companies are achieving profitability ahead of schedule, driven by multiple favorable factors that support value recovery [1] Industry Summary - Several innovative pharmaceutical companies are experiencing significant commercialization growth in their core products, with sales of key drugs like Zebutinib and Furmetinib exceeding expectations [1] - The performance improvement of these companies is accompanied by marginal profit enhancement [1] - Long-term support policies for the innovative pharmaceutical industry are being further refined, with ongoing optimization in payment and hospital admission processes, which may resolve existing development bottlenecks [1] - A global trend of interest rate cuts by major central banks is expected to benefit the long-term valuation of innovative pharmaceutical companies [1] Company Summary - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets to reflect the overall performance of related securities [1]